Mackenzie Financial
RPRX icon

Mackenzie Financial’s Royalty Pharma RPRX Stock Holding History

Mackenzie Financial’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Buy
270,457
+99,575
+58% +$5.18M 0.02% 504
2026
Q1 		$8.2M Sell
170,882
-32,940
-16% -$1.44M 0.01% 559
2025
Q4 		$7.93M Buy
203,822
+154,378
+312% +$5.89M 0.01% 549
2025
Q3 		$1.74M Sell
49,444
-18,798
-28% -$681K ﹤0.01% 882
2025
Q2 		$2.46M Sell
68,242
-279,136
-80% -$9.25M ﹤0.01% 747
2025
Q1 		$10.8M Buy
347,378
+205,356
+145% +$6.51M 0.02% 446
2024
Q4 		$3.62M Buy
142,022
+9,313
+7% +$247K ﹤0.01% 631
2024
Q3 		$3.75M Buy
132,709
+123,066
+1,276% +$3.41M 0.01% 600
2024
Q2 		$254K Sell
9,643
-18,742
-66% -$520K ﹤0.01% 1243
2024
Q1 		$862K Sell
28,385
-84,058
-75% -$2.48M ﹤0.01% 907
2023
Q4 		$3.16M Buy
112,443
+92,372
+460% +$2.54M ﹤0.01% 646
2023
Q3 		$542K Sell
20,071
-347
-2% -$10.3K ﹤0.01% 985
2023
Q2 		$627K Sell
20,418
-964
-5% -$32.6K ﹤0.01% 955
2023
Q1 		$770K Buy
+21,382
New +$793K ﹤0.01% 911
2022
Q4 		– Sell
-17,065
Closed -$686K – 1564
2022
Q3 		$686K Sell
17,065
-2,079
-11% -$88.8K ﹤0.01% 872
2022
Q2 		$805K Buy
+19,144
New +$785K ﹤0.01% 867
2022
Q1 		– Sell
-8,856
Closed -$353K – 1494
2021
Q4 		$353K Sell
8,856
-19,678
-69% -$764K ﹤0.01% 1087
2021
Q3 		$1.03M Buy
28,534
+3,634
+15% +$141K ﹤0.01% 910
2021
Q2 		$1.02M Hold
24,900
– – ﹤0.01% 868
2021
Q1 		$1.09M Hold
24,900
– – ﹤0.01% 800
2020
Q4 		$1.25M Buy
+24,900
New +$1.06M ﹤0.01% 679

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's RPRX Position: Q2 2026 in Review

Mackenzie Financial increased its Royalty Pharma (RPRX) stake by 58% in Q2 2026, buying an estimated $5.18M and bringing the position to 270,457 shares worth $15.2M. The position accounts for 0.02% of the portfolio, ranked #504.

Mackenzie Financial first reported a position in RPRX in Q4 2020 and has held it in 21 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Mackenzie Financial held 270,457 shares of Royalty Pharma worth $15.2M as of Q2 2026.
  • Mackenzie Financial bought 99,575 Royalty Pharma shares in Q2 2026, an estimated $5.18M.
  • Royalty Pharma made up 0.02% of Mackenzie Financial's portfolio in Q2 2026, its #504 holding.
  • Mackenzie Financial first reported a position in Royalty Pharma in Q4 2020 and has held it in 21 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.